Innate Pharma (IPHA) Free Cash Flow (2019 - 2024)
Historic Free Cash Flow for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$7.0 million.
- Innate Pharma's Free Cash Flow rose 7994.1% to -$7.0 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$41.6 million, marking a year-over-year increase of 3676.93%. This contributed to the annual value of -$7.8 million for FY2024, which is 7800.89% up from last year.
- Per Innate Pharma's latest filing, its Free Cash Flow stood at -$7.0 million for Q4 2024, which was up 7994.1% from -$34.7 million recorded in Q4 2023.
- Innate Pharma's 5-year Free Cash Flow high stood at $448163.8 for Q2 2022, and its period low was -$65.8 million during Q4 2021.
- Its 5-year average for Free Cash Flow is -$33.3 million, with a median of -$34.7 million in 2023.
- In the last 5 years, Innate Pharma's Free Cash Flow crashed by 773501.41% in 2020 and then soared by 10120.35% in 2022.
- Quarter analysis of 5 years shows Innate Pharma's Free Cash Flow stood at -$60.6 million in 2020, then dropped by 8.53% to -$65.8 million in 2021, then soared by 71.13% to -$19.0 million in 2022, then tumbled by 82.42% to -$34.7 million in 2023, then surged by 79.94% to -$7.0 million in 2024.
- Its last three reported values are -$7.0 million in Q4 2024, -$34.7 million for Q4 2023, and -$12.1 million during Q2 2023.